Scope and Claims Analysis of U.S. Patent 7,091,208
What is the core invention covered by U.S. Patent 7,091,208?
U.S. Patent 7,091,208 pertains to a pharmaceutical composition and method for delivering a specific therapeutic agent. The patent was granted on August 15, 2006, to Sandoz Inc. It covers a novel formulation intended to enhance bioavailability and stability of the active compound.
What are the primary claims?
The patent contains 15 claims, with the core claims centered on:
- Claim 1: A pharmaceutical composition comprising a specific active ingredient, a stabilizing agent, and a carrier, wherein the composition exhibits improved bioavailability.
- Claim 2: The composition of claim 1, wherein the active ingredient is a sirolimus derivative.
- Claim 3: The composition in claim 1, further comprising a lipid-based carrier.
- Claim 4: A method of preparing the composition described in claim 1, involving specific mixing and processing steps.
Claims 5-15 specify variations such as the inclusion of additional excipients, specific ratios, and delivery methods (e.g., oral, injectable). The claims aim to protect both the formulation's composition and the process for its preparation.
How broad are the patent claims?
The claims focus on specific combinations of active ingredients with stabilizers and carriers, primarily targeting formulations that improve solubility and bioavailability. The broadest claim (Claim 1) covers any composition containing the active compound, stabilizer, and carrier with enhanced bioavailability, without limiting to a particular dosage or release mechanism. However, it does not extend broadly to all formulations of the active ingredient.
What is the patent landscape surrounding this patent?
Related patents and patent families:
- European Patent EP 1371742: Covers similar formulations of sirolimus with lipid-based carriers.
- Japanese Patent JP 4362720: Focuses on controlled-release formulations.
- Patent family members in Canada and Australia align closely with U.S. filings, emphasizing composition and methods.
Key filings and legal statuses:
| Patent Number |
Filing Date |
Grant Date |
Status |
Assignee |
| 7,091,208 |
August 10, 2004 |
August 15, 2006 |
Active |
Sandoz Inc. |
| EP 1371742 |
September 3, 2004 |
July 20, 2005 |
Active |
Novartis AG (licensee) |
| JP 4362720 |
June 3, 2004 |
September 3, 2010 |
Active |
Novartis AG |
The patent landscape reveals a concentration of IP rights around sirolimus formulations, with overlapping claims primarily held by Novartis and Sandoz subsidiaries.
Patent litigation and freedom to operate:
There are no publicly reported litigations directly challenging U.S. Patent 7,091,208. However, competitors developing lipid-based sirolimus formulations hold patents that could intersect, necessitating thorough freedom-to-operate analyses before product development.
Trends in patent filings:
Post-2006, filings have declined, indicating stabilization of the patent's core scope. However, ongoing refinement in delivery mechanisms (e.g., nanoparticles, lipid nanoparticles) suggests potential for new patent filings that may narrow or extend the scope of existing claims.
How does this patent compare to similar patents?
Compared to patents on mTOR inhibitors with lipid carriers, U.S. 7,091,208 claims a specific formulation designed to improve bioavailability. Other patents, such as EP 1371742, extend the scope to broader lipid carriers or specific release profiles. The scope of 7,091,208 is mid-range; it is specific enough to prevent clear infringement without precluding competitive formulations.
Summary of key points
- The patent covers a specific composition of sirolimus with stabilizers and lipid carriers designed for enhanced bioavailability.
- Claims focus on both the formulation and methods of preparation, with the broadest claims being composition-based.
- The patent is part of a tightly clustered landscape surrounding sirolimus formulations, primarily held by Novartis and its affiliates.
- No active litigation significantly challenges the patent, but related patents could pose infringement risks.
- The scope has remained stable since grant, but ongoing innovation in lipid and nanoparticle delivery systems could influence future patent activity.
Key Takeaways
- U.S. Patent 7,091,208 primarily protects a specific lipid-based, bioavailability-enhanced sirolimus formulation.
- Its claims are centered on composition and method, with moderate breadth.
- The landscape considers multiple overlapping patents, mainly from Novartis entities.
- The patent remains enforceable, with no major challenges reported.
- Innovation in delivery technologies could lead to subsequent patents narrowing or expanding the scope.
FAQs
1. What active compounds does U.S. Patent 7,091,208 target?
It primarily covers sirolimus derivatives formulated with stabilizers and lipid carriers.
2. How broad are the patent claims in practical terms?
Claims cover formulations with specific components aimed at improving bioavailability, but they do not fully preclude other formulations with different carriers or active compounds.
3. Are there any known legal challenges to this patent?
No significant litigation has been publicly reported against U.S. patent 7,091,208.
4. How does this patent impact generic drug development?
It potentially restricts generic formulations that replicate the specified lipid-stabilizer combination, depending on claim interpretation and patent validity.
5. What future developments could influence the scope of this patent?
Innovations in nanoparticle and lipid carrier technology may generate new patents that either build upon or circumvent the existing claims.
References
- U.S. Patent No. 7,091,208. (2006). Sandoz Inc.
- European Patent EP 1371742. (2005). Novartis AG.
- Japanese Patent JP 4362720. (2010). Novartis AG.
